Science & Technology
Advancing Diabetic Foot Ulcer Treatment with Provasliex, a Controlled PDGF Release Hydrogel for Promoting Vascularization and Managing Overactive Inflammation
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43DK141293-01
Award Ceiling
$325K
Award Floor
$325K
Close Date
Aug 31, 2025
Total Funding
$325K
Expected Awards
1
Posted Date
Sep 5, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R43DK141293-01
Description
SBIR Phase Phase I award: "Advancing Diabetic Foot Ulcer Treatment with Provasliex, a Controlled PDGF Release Hydrogel for Promoting Vascularization and Managing Overactive Inflammation" awarded to GELSANA THERAPEUTICS INC in AURORA, Colorado. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $324,992. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, HUBZone businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.